Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease

• Status: Unknown status
• Trial end date: 2014-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators propose to study the efficacy and safety of three-week antifungal therapy with caspofungin in hospitalized patients with proven or probable IPA underlying chronic obstructive pulmonary disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The First Affiliated Hospital of Guangzhou Medical University
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Caspofungin; Echinocandins

Criteria

Inclusion Criteria:

• Proven invasive pulmonary aspergillosis

• Probable invasive pulmonary aspergillosis

• Hospitalized in respiratory wards

• Not having received an empirical antifungal therapy for 72h before inclusion

Exclusion Criteria:

• A history of allergy to echinocandins

• Severe renal failure, severe hepatic insufficiency

• Inadequately treated bacterial infection

• Documented HIV infection

• Status of pregnancy or lactation